Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.21 USD | -2.31% | -0.26% | -10.95% |
Business Summary
Number of employees: 264
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Treatments for B-cell Diseases
100.0
%
| 3 | 100.0 % | 234 | 100.0 % | +8,290.02% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 3 | 100.0 % | 234 | 100.0 % | +8,290.02% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 93-05-17 |
Sean Power
DFI | Director of Finance/CFO | 42 | 11-12-28 |
Jenna A. Bosco
IRC | Investor Relations Contact | - | 11-11-30 |
Adam Waldman
PRN | Corporate Officer/Principal | - | 18-06-03 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Weiss
CEO | Chief Executive Officer | 58 | 93-05-17 |
Laurence Charney
BRD | Director/Board Member | 77 | 12-02-29 |
Kenneth Hoberman
BRD | Director/Board Member | 59 | 14-12-14 |
Yann Echelard
BRD | Director/Board Member | 60 | 12-11-08 |
Daniel Hume
BRD | Director/Board Member | 57 | 15-03-31 |
Sagar Lonial
BRD | Director/Board Member | 57 | 20-04-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 154,462,081 | 140,404,745 ( 90.90 %) | 41,309 ( 0.0267 %) | 90.90 % |
Company contact information
TG Therapeutics, Inc.
3020 Carrington Mill Boulevard Suite 475
27560, Morrisville
+212 554 4484
http://www.tgtherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.95% | 2.2B | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |
- Stock
- Equities
- Stock TG Therapeutics, Inc. - Nasdaq
- Company TG Therapeutics, Inc.